United States
Print page content Print
Increase text size Decrease text size
Text Size

FELOCELL® 4

Helps prevent feline viral rhinotracheitis (FVR), feline respiratory disease caused by feline calicivirus (FCV), feline panleukopenia (FPL) and feline chlamydiosis

FELOCELL 4

FELOCELL 4 is for vaccination of healthy cats as an aid in preventing feline viral rhinotracheitis (FVR) caused by feline herpesvirus-1, respiratory disease caused by feline calicivirus (FCV), feline panleukopenia (FPL) caused by feline parvovirus (FPV), and feline chlamydiosis caused by Chlamydia psittaci.

Expand All
    • FELOCELL 4 is a non-adjuvanted modified-live virus (MLV) vaccine.
    • Contains attenuated strains of feline rhinotracheitis virus, calicivirus and panleukopenia virus (Johnson Snow Leopard strain) and C. psittaci propagated on established cell lines.
    • Safety of FELOCELL 4 was demonstrated in field trials involving 2,288 cats. The majority of cats experienced no serious post-vaccination reactions attributable to the vaccine. However, approximately 1% of the vaccinated cats experienced lethargy, anorexia and fever after vaccination.
    • Packaged in freeze-dried form with inert gas in place of vacuum.
    • Customer-friendly packaging includes peel-off labels for faster and more accurate record-keeping, a color-coded organizing system, and an easy-open safety band.
    • FELOCELL 4 is supported by our Companion Animal Immunization Support Guarantee (ISG).
  • DIRECTIONS:

    1. General Directions: Vaccination of healthy cats is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 1 mL intramuscularly or subcutaneously.


    2. Primary Vaccination: Healthy cats 12 weeks of age or older should receive 2 doses administered 3-4 weeks apart. Cats vaccinated at less than 12 weeks of age should be revaccinated at 12 weeks of age.


    3. Revaccination: Annual revaccination with a single dose is recommended, although, as recommended by the American Veterinary Medical Association and its Council on Biologic and Therapeutic Agents, the attending veterinarian should determine the frequency of revaccination based on the animal's lifestyle and risk of exposure.*


    *American Veterinary Medical Association, Position Statements on Biologics, June 2001.


PRECAUTIONS:

1. Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
4. Burn containers and all unused contents.
5. Contains gentamicin as preservative.
6. Vaccination of pregnant queens should be avoided.
7. The use of this product has been associated with fever, anorexia, and lethargy in 1% of vaccinated cats, often occurring in clusters in association with multiple concurrent vaccinations. The onset is typically delayed 7-21 days after vaccination. Symptoms may persist for 3-30 days with an average of 12 days after onset. Veterinary intervention may be required. When treatment is necessary, supportive care, steroids, and antibiotics have been utilized.
8. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
9. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

Technical inquiries should be directed to Zoetis Veterinary Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).

For veterinary use only